Accord Healthcare recalls Rosuvastatin tablets for manufacturing deviations
Accord Healthcare is recalling Rosuvastatin 10 mg tablets due to manufacturing deviations identified during FDA inspection. No illnesses or injuries have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a prescription medication due to manufacturing deviations. This constitutes a risk-of-harm product where injury has not yet been reported, but potential for adverse health consequences exists if deviations affected drug quality, potency, or safety.
Plain-English summary
Accord Healthcare, Inc. is recalling Rosuvastatin 10 mg tablets due to Current Good Manufacturing Practice (CGMP) deviations identified during a U.S. Food and Drug Administration inspection. The recall affects 56,862 bottles distributed across the United States, Puerto Rico, and Canada.
The affected product is packaged in 90-count and 1,000-count bottles. Multiple batch codes are included in this recall, with expiration dates ranging from August 2023 through July 2025.
No illnesses or injuries related to this recall have been reported. Patients currently taking recalled Rosuvastatin should contact their healthcare provider or pharmacist about their treatment options. Do not use the product after the expiration date printed on the bottle.
For questions or to report adverse effects, consumers and healthcare providers should contact Accord Healthcare, Inc. or the FDA.
The recalled product
- Product
- ROSUVASTATIN (ROSUVASTATIN)
- Brand
- ROSUVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- Affected units
- 56,862
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2006824
- Exp. Date 11/30/2023
- P2102223
- Exp. Date 3/31/2024
- b) P2004949
- Exp. Date 8/31/2023
- P2004948
- P2004950
- P2004953
- P2004954
- P2004956
- P2004955
- P2004957
- P2004958
- P2004959
- P2005252
- Exp. Date 9/30/2023
- P2006607
- P2101368
- Exp. Date 2/29/2024
UPCs (2)
- 316729285155
- 316729285179
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · ROSUVASTATIN
- ModerateRosuvastatin tablets recalled after failing a dissolution specification
FDA (Drugs) · 2026-01-14
- HighFDA Recalls Rosuvastatin Tablets Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModerateRosuvastatin Tablets 5mg Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModerateRosuvastatin tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29